RESEARCH OVERVIEW

Here is an overview of all the trials the Band has funded since its inception in 2007.

PROJECT TITLERESEARCHERINSTITUTIONAMOUNT
Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients with High-Risk Neuroblastoma and GD2-Positive TumorsNai-Kong V. Cheung MD, PhD & Ellen Basu, MD, PhDMemorial Sloan Kettering Cancer Center$1,500,000
GMP Manufacture and Clinical Testing of Hu3F8-IgG1n (Turbo 3F8)Nai-Kong V. Cheung MD, PhD & Stephen S. RobertsMemorial Sloan Kettering Cancer Center$1,500,000
GMP Manufacture and Clinical Testing of an Hu3F8 Bi-Specific AntibodyNai-Kong V. Cheung MD, PhDMemorial Sloan Kettering Cancer Center$2,000,000
MIBG TrialShakeel Modak, MDMemorial Sloan Kettering Cancer Center$40,000
Combination of Cell-Mediated and Antibody-Mediated Immunotherapy for High-Risk Neuroblastoma: Phase I Study of Haploidentical Natural Killer Cells plus Humanized 3F8Shakeel Modak, MDMemorial Sloan Kettering Cancer Center$700,000
Bivalent Vaccine Plus Beta-Glucan for High-Risk Neuroblastoma in First RemissionBrian H. Kushner, MDMemorial Sloan Kettering Cancer Center$300,000
Reduced Dose Radiotherapy TrialDr. WoldenMemorial Sloan Kettering Cancer Center$5,000
Molecular Annotation for Treatment of Childhood Cancers (MATCH) Trial: NeuroblastomaJohn Maris, MD & Yael Mosse, MDChildren’s Hospital of Philadelphia (CHOP)$400,000
Molecular Annotation for Treatment of Childhood Cancers (MATCH) Trial: NeuroblastomaWing Leung, MD, PhDSt. Jude Children’s Research Hospital$45,000
New Approaches to Neuroblastoma Therapy (NANT)VariousConsortium of Leading Hospitals$125,000
 The John K. Bartosz Memorial Fellowship in Pediatric ImmunotherapyMemorial Sloan Kettering Cancer Center $200,000
Combination immunotherapy with targeted radiotherapy in children with neuroblastomaJuliet Gray, MD; Paul Sondel MD, PhD; Holger Lode, MD; Mark Gaze, MDUniversity Hospital London, University Hospital Southampton UK, University of Wisconsin, Madison, University Medicine, Greifswald, Germany$125,000